IDH1-R132G Antilichaam / Isocitraat Dehydrogenase R132G mutant

The gene represented in this entry is involved in disease pathogenesis. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R (-) -2-hydroxyglutarate. Elevated levels of R (-) -2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. Genetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to Cys, Gly or His abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R (-) -2-hydroxyglutarate.

Immunohistochemistry (FFPE) : 1-2 µg/mL, Western blot: 2-4 µg/mL

O75874

Human

A recombinant partial protein from human IDH1 protein with the R132G mutation was used as the immunogen for the IDH1-R132G antibody.

IDH1.R132G/13054R

IHC-P, WB

Protein A affinity

Purified

This IDH1-R132G antibody is available for research use only.

Aliquot the IDH1-R132G antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05% sodium azide

Optimal dilution of the IDH1-R132G antibody should be determined by the researcher.

Cytoplasm

Western blot testing of human kidney tissue lysate with IDH1-R132G antibody (clone IDH1.R132G/13054R) . Predicted molecular weight ~47 kDa.